The topical treatment with 1% A63 extract diminished OXA-induced AD-like symptoms and cutaneous inflammation by attenuating the infiltration of inflammatory cells and suppressing the expression of atopic markers through the inactivation of their upstream MAPK and STAT signaling targets. Here, SOAT1 is linked to Alzheimer disease.